Core Viewpoint - The approval of GPN01530 by the FDA for clinical research marks a significant step in the company's global strategy in the field of radiopharmaceuticals for cancer diagnosis and treatment [1] Group 1: Product Development - GPN01530 is the company's first self-developed radiopharmaceutical product to receive FDA approval for clinical research [1] - The successful approval of GPN01530 provides an important paradigm for the international development of the company's radiopharmaceutical product pipeline [1] Group 2: Global Strategy - The company plans to leverage a "dual submission" international registration pathway to advance the global research and registration of GPN01530 [1] - This approval is seen as a milestone in the company's global research and registration process for radiopharmaceuticals, reflecting its comprehensive capabilities in advanced nuclear medicine technology [1] Group 3: Future Prospects - The company aims to deepen its global development strategy in the radiopharmaceutical sector and actively promote international clinical research and registration of more self-developed innovative radiopharmaceutical products [1] - The goal is to continuously enhance the company's core competitiveness and international influence in the field of radiopharmaceuticals for cancer diagnosis and treatment [1]
远大医药：自主研发的重磅全球创新放射性核素偶联药物 GPN01530 在美国获批开展临床研究